A case control study of sarcosine as an early prostate cancer detection biomarker Urological oncology

BMC Urology

Volumn 15, Issue 1, 2015, Pages

  Ankerst, Donna P ^a,b,c   Liss, Michael ^b   Zapata, David ^b   Hoefler, Josef ^a   Thompson, Ian M ^b   Leach, Robin J ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b University of Texas Health Science Center   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Prostate cancer; Prostate specific antigen; Sarcosine

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SARCOSINE; TUMOR MARKER;

ADULT; AGE; AGED; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; ELECTROSPRAY MASS SPECTROMETRY; FAMILY HISTORY; GLEASON SCORE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETER; POPULATION BASED CASE CONTROL STUDY; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; RACE; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RISK ASSESSMENT; SARCOSINE BLOOD LEVEL; BLOOD; EARLY CANCER DIAGNOSIS; EVALUATION STUDY; MIDDLE AGED; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SARCOSINE; SENSITIVITY AND SPECIFICITY;

EID: 84942991889     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/s12894-015-0095-5     Document Type: Article

References (9)

1. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457(7231):910-4.
2. Cernei N, Heger Z, Gumulec J, Zitka O, Masarik M, Babula P, et al. Sarcosine as a potential prostate cancer biomarker - a review. Int J Mol Sci. 2013;14(7):13893-908.
3. de Vogel S, Ulvik A, Meyer K, Ueland PM, Nygard O, Vollset SE, et al. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer - a large nested case-control study within the JANUS cohort in Norway. Int J Cancer. 2014;134(1):197-206.
4. Koutros S, Meyer TE, Fox SD, Issaq HJ, Veenstra TD, Huang WY, et al. Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Carcinogenesis. 2013;34(10):2281-5.
5. Liang Y, Ankerst DP, Ketchum NS, Ercole B, Shah G, Shaughnessy JD, et al. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol. 2011;185(1):104-10.
6. Lucarelli G, Fanelli M, Larocca AM, Germinario CA, Rutigliano M, Vavallo A, et al. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate. 2012;72(15):1611-21.
7. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. European Urol. 2010;58(1):12-8. discussion 20-21.
8. Wu H, Liu T, Ma C, Xue R, Deng C, Zeng H, et al. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization. Anal Bioanal Chem. 2011;401(2):635-46.
9. Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX, Yao XD. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis. 2011;14(2):166-72.